Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at in...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Rheumatology 2021-04, Vol.17 (4), p.238-243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 243 |
|---|---|
| container_issue | 4 |
| container_start_page | 238 |
| container_title | Nature reviews. Rheumatology |
| container_volume | 17 |
| creator | Perez-Chada, Lourdes M. Haberman, Rebecca H. Chandran, Vinod Rosen, Cheryl F. Ritchlin, Christopher Eder, Lihi Mease, Philip Reddy, Soumya Ogdie, Alexis Merola, Joseph F. Scher, Jose U. |
| description | The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: ‘increased risk for PsA’, ‘psoriasis with asymptomatic synovio-entheseal imaging abnormalities’ and ‘psoriasis with musculoskeletal symptoms not explained by other diagnosis’. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies. |
| doi_str_mv | 10.1038/s41584-021-00578-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7997804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A656431642</galeid><sourcerecordid>A656431642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638t-c07022732d1bcf18b9cd7ce192d852c83d3d02ee9b80511293188d3a48fce4d53</originalsourceid><addsrcrecordid>eNp9ksuKFDEUhgtRnIu-gAsJCDKbGnOpVCUuhKG9woAbXYd06lRXhlRSJimhX8DnNj09006LSBYJJ9_5T_LzV9ULgi8JZuJNaggXTY0pqTHmnajpo-qUdFzWjcDN4_tzJ_FJdZbSDcZt0wr5tDphjAspiDitfq2CT-DTklCGOFkfXNhs0RAimiMYZ7012qF51AkSCgOaU4hWZ2uQjnmMNtt0Sy8JkPUoQgIdzYhSXnoL6e2usrhcoBgmpNF7cPNokTmM3YHbZ9WTQbsEz-_28-r7xw_fVp_r66-fvqyurmvTMpFrgztMacdoT9ZmIGItTd8ZIJL2glMjWM96TAHkWmBOCJWMCNEz3YjBQNNzdl692-vOy3qC3oDPUTs1RzvpuFVBW3V84-2oNuGn6qTsiqlF4OJOIIYfC6SsJpsMOKc9hCUp2khMKGFUFPTVX-hNWKIv31OUY847KssDD9RGO1DWD6HMNTtRddXytmGkbWihLv9BldXDZIuXMNhSP2p4_aBhBO3ymIJbsi3GH4N0D5oYUoowHMwgWO1ipvYxUyVm6jZmatf08qGNh5b7XBWA7YFUrvwG4p-__0f2N5Tu3uk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2505572929</pqid></control><display><type>article</type><title>Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Perez-Chada, Lourdes M. ; Haberman, Rebecca H. ; Chandran, Vinod ; Rosen, Cheryl F. ; Ritchlin, Christopher ; Eder, Lihi ; Mease, Philip ; Reddy, Soumya ; Ogdie, Alexis ; Merola, Joseph F. ; Scher, Jose U.</creator><creatorcontrib>Perez-Chada, Lourdes M. ; Haberman, Rebecca H. ; Chandran, Vinod ; Rosen, Cheryl F. ; Ritchlin, Christopher ; Eder, Lihi ; Mease, Philip ; Reddy, Soumya ; Ogdie, Alexis ; Merola, Joseph F. ; Scher, Jose U.</creatorcontrib><description>The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: ‘increased risk for PsA’, ‘psoriasis with asymptomatic synovio-entheseal imaging abnormalities’ and ‘psoriasis with musculoskeletal symptoms not explained by other diagnosis’. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies.</description><identifier>ISSN: 1759-4790</identifier><identifier>EISSN: 1759-4804</identifier><identifier>DOI: 10.1038/s41584-021-00578-2</identifier><identifier>PMID: 33589818</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/2779 ; 692/4023/1670/2766/1900 ; Arthritis ; Consensus Statement ; Identification and classification ; Medicine ; Medicine & Public Health ; Population studies ; Psoriasis ; Psoriatic arthritis ; Quality of life ; Remission ; Rheumatology ; Risk factors ; Standardization ; Terminology</subject><ispartof>Nature reviews. Rheumatology, 2021-04, Vol.17 (4), p.238-243</ispartof><rights>The Author(s) 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c638t-c07022732d1bcf18b9cd7ce192d852c83d3d02ee9b80511293188d3a48fce4d53</citedby><cites>FETCH-LOGICAL-c638t-c07022732d1bcf18b9cd7ce192d852c83d3d02ee9b80511293188d3a48fce4d53</cites><orcidid>0000-0002-6620-0457 ; 0000-0002-7119-8136</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41584-021-00578-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41584-021-00578-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33589818$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perez-Chada, Lourdes M.</creatorcontrib><creatorcontrib>Haberman, Rebecca H.</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Rosen, Cheryl F.</creatorcontrib><creatorcontrib>Ritchlin, Christopher</creatorcontrib><creatorcontrib>Eder, Lihi</creatorcontrib><creatorcontrib>Mease, Philip</creatorcontrib><creatorcontrib>Reddy, Soumya</creatorcontrib><creatorcontrib>Ogdie, Alexis</creatorcontrib><creatorcontrib>Merola, Joseph F.</creatorcontrib><creatorcontrib>Scher, Jose U.</creatorcontrib><title>Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study</title><title>Nature reviews. Rheumatology</title><addtitle>Nat Rev Rheumatol</addtitle><addtitle>Nat Rev Rheumatol</addtitle><description>The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: ‘increased risk for PsA’, ‘psoriasis with asymptomatic synovio-entheseal imaging abnormalities’ and ‘psoriasis with musculoskeletal symptoms not explained by other diagnosis’. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies.</description><subject>692/308/2779</subject><subject>692/4023/1670/2766/1900</subject><subject>Arthritis</subject><subject>Consensus Statement</subject><subject>Identification and classification</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Population studies</subject><subject>Psoriasis</subject><subject>Psoriatic arthritis</subject><subject>Quality of life</subject><subject>Remission</subject><subject>Rheumatology</subject><subject>Risk factors</subject><subject>Standardization</subject><subject>Terminology</subject><issn>1759-4790</issn><issn>1759-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ksuKFDEUhgtRnIu-gAsJCDKbGnOpVCUuhKG9woAbXYd06lRXhlRSJimhX8DnNj09006LSBYJJ9_5T_LzV9ULgi8JZuJNaggXTY0pqTHmnajpo-qUdFzWjcDN4_tzJ_FJdZbSDcZt0wr5tDphjAspiDitfq2CT-DTklCGOFkfXNhs0RAimiMYZ7012qF51AkSCgOaU4hWZ2uQjnmMNtt0Sy8JkPUoQgIdzYhSXnoL6e2usrhcoBgmpNF7cPNokTmM3YHbZ9WTQbsEz-_28-r7xw_fVp_r66-fvqyurmvTMpFrgztMacdoT9ZmIGItTd8ZIJL2glMjWM96TAHkWmBOCJWMCNEz3YjBQNNzdl692-vOy3qC3oDPUTs1RzvpuFVBW3V84-2oNuGn6qTsiqlF4OJOIIYfC6SsJpsMOKc9hCUp2khMKGFUFPTVX-hNWKIv31OUY847KssDD9RGO1DWD6HMNTtRddXytmGkbWihLv9BldXDZIuXMNhSP2p4_aBhBO3ymIJbsi3GH4N0D5oYUoowHMwgWO1ipvYxUyVm6jZmatf08qGNh5b7XBWA7YFUrvwG4p-__0f2N5Tu3uk</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Perez-Chada, Lourdes M.</creator><creator>Haberman, Rebecca H.</creator><creator>Chandran, Vinod</creator><creator>Rosen, Cheryl F.</creator><creator>Ritchlin, Christopher</creator><creator>Eder, Lihi</creator><creator>Mease, Philip</creator><creator>Reddy, Soumya</creator><creator>Ogdie, Alexis</creator><creator>Merola, Joseph F.</creator><creator>Scher, Jose U.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6620-0457</orcidid><orcidid>https://orcid.org/0000-0002-7119-8136</orcidid></search><sort><creationdate>20210401</creationdate><title>Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study</title><author>Perez-Chada, Lourdes M. ; Haberman, Rebecca H. ; Chandran, Vinod ; Rosen, Cheryl F. ; Ritchlin, Christopher ; Eder, Lihi ; Mease, Philip ; Reddy, Soumya ; Ogdie, Alexis ; Merola, Joseph F. ; Scher, Jose U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638t-c07022732d1bcf18b9cd7ce192d852c83d3d02ee9b80511293188d3a48fce4d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/308/2779</topic><topic>692/4023/1670/2766/1900</topic><topic>Arthritis</topic><topic>Consensus Statement</topic><topic>Identification and classification</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Population studies</topic><topic>Psoriasis</topic><topic>Psoriatic arthritis</topic><topic>Quality of life</topic><topic>Remission</topic><topic>Rheumatology</topic><topic>Risk factors</topic><topic>Standardization</topic><topic>Terminology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perez-Chada, Lourdes M.</creatorcontrib><creatorcontrib>Haberman, Rebecca H.</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Rosen, Cheryl F.</creatorcontrib><creatorcontrib>Ritchlin, Christopher</creatorcontrib><creatorcontrib>Eder, Lihi</creatorcontrib><creatorcontrib>Mease, Philip</creatorcontrib><creatorcontrib>Reddy, Soumya</creatorcontrib><creatorcontrib>Ogdie, Alexis</creatorcontrib><creatorcontrib>Merola, Joseph F.</creatorcontrib><creatorcontrib>Scher, Jose U.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature reviews. Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perez-Chada, Lourdes M.</au><au>Haberman, Rebecca H.</au><au>Chandran, Vinod</au><au>Rosen, Cheryl F.</au><au>Ritchlin, Christopher</au><au>Eder, Lihi</au><au>Mease, Philip</au><au>Reddy, Soumya</au><au>Ogdie, Alexis</au><au>Merola, Joseph F.</au><au>Scher, Jose U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study</atitle><jtitle>Nature reviews. Rheumatology</jtitle><stitle>Nat Rev Rheumatol</stitle><addtitle>Nat Rev Rheumatol</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>17</volume><issue>4</issue><spage>238</spage><epage>243</epage><pages>238-243</pages><issn>1759-4790</issn><eissn>1759-4804</eissn><abstract>The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: ‘increased risk for PsA’, ‘psoriasis with asymptomatic synovio-entheseal imaging abnormalities’ and ‘psoriasis with musculoskeletal symptoms not explained by other diagnosis’. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33589818</pmid><doi>10.1038/s41584-021-00578-2</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6620-0457</orcidid><orcidid>https://orcid.org/0000-0002-7119-8136</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-4790 |
| ispartof | Nature reviews. Rheumatology, 2021-04, Vol.17 (4), p.238-243 |
| issn | 1759-4790 1759-4804 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7997804 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | 692/308/2779 692/4023/1670/2766/1900 Arthritis Consensus Statement Identification and classification Medicine Medicine & Public Health Population studies Psoriasis Psoriatic arthritis Quality of life Remission Rheumatology Risk factors Standardization Terminology |
| title | Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A33%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consensus%20terminology%20for%20preclinical%20phases%20of%20psoriatic%20arthritis%20for%20use%20in%20research%20studies:%20results%20from%20a%20Delphi%20consensus%20study&rft.jtitle=Nature%20reviews.%20Rheumatology&rft.au=Perez-Chada,%20Lourdes%20M.&rft.date=2021-04-01&rft.volume=17&rft.issue=4&rft.spage=238&rft.epage=243&rft.pages=238-243&rft.issn=1759-4790&rft.eissn=1759-4804&rft_id=info:doi/10.1038/s41584-021-00578-2&rft_dat=%3Cgale_pubme%3EA656431642%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2505572929&rft_id=info:pmid/33589818&rft_galeid=A656431642&rfr_iscdi=true |